Semaglutide vs Tirzepatide vs Retatrutide: Receptor Targets Compared

The short answer

The three differ by receptor count. Semaglutide is a single agonist that binds the GLP-1 receptor. Tirzepatide is a dual agonist that binds both the GIP and GLP-1 receptors. Retatrutide - listed in this catalog as GLP-3 (RT) - is a triple agonist that adds the glucagon receptor to those two. Each additional receptor changes the downstream signalling that researchers observe, and each also changes how much published human data exists: semaglutide has the largest body of trial literature, tirzepatide a substantial one, and retatrutide the smallest and most recent.

What a dual or triple agonist actually means

A receptor agonist is a molecule that binds a receptor and switches it on. A dual agonist is one molecule that activates two different receptors rather than two molecules given together - the distinction matters in research because a single molecule produces one pharmacokinetic profile instead of two overlapping ones. A triple agonist extends the same principle to a third receptor.

The incretin receptors involved are distinct. GLP-1 and GIP are both incretin hormones released from the gut, and their receptors sit on different tissues and couple to different downstream cascades. The glucagon receptor that retatrutide adds is a separate target again, and in published work it is associated with energy-expenditure signalling rather than incretin signalling. Adding receptors is therefore not simply an increase in strength - it changes which pathways are engaged at once.

Evidence quality is the real difference

For a researcher choosing a reference material, the more useful axis is how much published literature exists to compare against. Semaglutide has been studied in large multi-year human trials with published cardiovascular and metabolic endpoints. Tirzepatide has a substantial and growing trial record. Retatrutide is the newest of the three and its human data is early-phase, meaning smaller cohorts, shorter durations and fewer independent replications.

That gap is worth stating plainly: a compound being newer is not evidence that it is stronger. It is evidence that less is known about it. Research designs that assume the triple agonist is simply “more” of the dual agonist are not supported by the published record.

Laboratory handling

All three ship as lyophilized powders and are reconstituted in the laboratory with bacteriostatic water. All three are peptides and are degraded by heat, light and repeated freeze-thaw cycles, so the same cold, dark storage discipline applies to each. Reconstituted material has a shorter working life than lyophilized powder in every case.